News & Updates

Renal composite outcomes (RCO) appear to be less favourable among type 2 diabetes (T2D) patients with chronic kidney disease (CKD) treated with insulin and sodium-glucose cotransporter 2 inhibitors (SGLT2i), a recent Japan study has found.

Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.

A novel artificial intelligence platform that integrates multidimensional data to deliver precision nutrition and health recommendations not only helps to induce remission in type 2 diabetes but also to normalize a range of glycaemic and extraglycaemic parameters, as shown in a study presented at the 82nd American Diabetes Association (ADA) Scientific Sessions.

Higher consumption of dairy products is associated with a lower risk of type 2 diabetes (T2D) among US adults, according to a nationally representative study presented at ADA 2022.

Automating insulin delivery with an open-source algorithm that is run on a smartphone proves safe and effective in the management of type 1 diabetes (T1D), as shown in the results of Community Derived Automated Insulin Delivery (CREATE) trial.

Patients with type 2 diabetes (T2D) who lose more weight appear to have better quality of life (QoL), an effect that is independent of treatments received, according to a study presented at the recent 82nd Scientific Sessions by the American Diabetes Association (ADA 2022).

Central obesity, as assessed by the waist-to-hip ratio (WHR), is very common in patients with axial spondyloarthritis (axSpA), particularly in women, reveals a recent study. This modifiable comorbidity may result in worse quality of life, worse disease activity, and greater impairment of functional ability.